EPS Bio Technology Corp.

TPEX:4183 Stock Report

Market Cap: NT$562.9m

EPS Bio Technology Past Earnings Performance

Past criteria checks 4/6

EPS Bio Technology has been growing earnings at an average annual rate of 3.1%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 0.4% per year. EPS Bio Technology's return on equity is 9.7%, and it has net margins of 6.2%.

Key information

3.1%

Earnings growth rate

3.1%

EPS growth rate

Medical Equipment Industry Growth11.5%
Revenue growth rate0.4%
Return on equity9.7%
Net Margin6.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Apr 16
Should You Or Shouldn't You: A Dividend Analysis on EPS Bio Technology Corp. (GTSM:4183)

Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

Mar 20
Will EPS Bio Technology (GTSM:4183) Multiply In Value Going Forward?

Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Feb 22
Here's Why We Think EPS Bio Technology's (GTSM:4183) Statutory Earnings Might Be Conservative

Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Feb 01
Do Fundamentals Have Any Role To Play In Driving EPS Bio Technology Corp.'s (GTSM:4183) Stock Up Recently?

Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Jan 04
Should EPS Bio Technology Corp. (GTSM:4183) Be Part Of Your Dividend Portfolio?

Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

Dec 14
Is EPS Bio Technology (GTSM:4183) Likely To Turn Things Around?

We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Nov 23
We Think EPS Bio Technology's (GTSM:4183) Statutory Profit Might Understate Its Earnings Potential

Revenue & Expenses Breakdown

How EPS Bio Technology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4183 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24485306234
30 Jun 24498346034
31 Mar 24477306033
31 Dec 23470215833
30 Sep 23424205432
30 Jun 23454245732
31 Mar 23442255531
31 Dec 22463256131
30 Sep 22506366031
30 Jun 22485255931
31 Mar 22504265931
31 Dec 21480195532
30 Sep 2145175432
30 Jun 21435155532
31 Mar 21459225732
31 Dec 20478326030
30 Sep 20497346032
30 Jun 20489286033
31 Mar 20466195833
31 Dec 19459185533
30 Sep 19437335532
30 Jun 19443315332
31 Mar 19445415232
31 Dec 18414165431
30 Sep 18431135230
30 Jun 1840495329
31 Mar 18390-125529
31 Dec 1742035430
30 Sep 1743426733
30 Jun 1745346934
31 Mar 17466276034
31 Dec 16467296634
30 Sep 16420185533
30 Jun 16426335232
31 Mar 16416245930
31 Dec 15425375030
30 Sep 15426295232
30 Jun 1541975534
31 Mar 15372-135636
31 Dec 14324-335637
30 Sep 14339-265637
30 Jun 14353-185537
31 Mar 14369-45337

Quality Earnings: 4183 has a high level of non-cash earnings.

Growing Profit Margin: 4183's current net profit margins (6.2%) are higher than last year (4.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4183's earnings have grown by 3.1% per year over the past 5 years.

Accelerating Growth: 4183's earnings growth over the past year (54.8%) exceeds its 5-year average (3.1% per year).

Earnings vs Industry: 4183 earnings growth over the past year (54.8%) exceeded the Medical Equipment industry 5%.

Return on Equity

High ROE: 4183's Return on Equity (9.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 18:29
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

EPS Bio Technology Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pinghan HsiehCapital Securities Corporation